Medizinische Universität Graz - Research portal
Selected Publication:
SHR Neuro Cancer Cardio Lipid Metab Microb
Rinnerthaler, G; Gampenrieder, SP; Greil, R.
HER2 Directed Antibody-Drug-Conjugates beyond T-DM1 in Breast Cancer.
Int J Mol Sci. 2019; 20(5):
Doi: 10.3390/ijms20051115
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Leading authors Med Uni Graz
- Rinnerthaler Gabriel
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Since the discovery of the human epidermal growth factor receptor 2 (HER2) as an oncogenic driver in a subset of breast cancers and the development of HER2 directed therapies, the prognosis of HER2 amplified breast cancers has improved meaningfully. Next to monoclonal anti-HER2 antibodies and tyrosine kinase inhibitors, the antibody-drug conjugate T-DM1 is a pillar of targeted treatment of advanced HER2-positive breast cancers. Currently, several HER2 directed antibody-drug conjugates are under clinical investigation for HER2 amplified but also HER2 expressing but not amplified breast tumors. In this article, we review the current preclinical and clinical evidence of the investigational drugs A166, ALT-P7, ARX788, DHES0815A, DS-8201a, RC48, SYD985, MEDI4276 and XMT-1522.
- Find related publications in this database (using NLM MeSH Indexing)
- Ado-Trastuzumab Emtansine - administration & dosage
- Antineoplastic Agents, Immunological - therapeutic use
- Breast Neoplasms - drug therapy
- Clinical Trials as Topic - administration & dosage
- Female - administration & dosage
- Humans - administration & dosage
- Maytansine - analogs & derivatives, therapeutic use
- Protein Kinase Inhibitors - therapeutic use
- Receptor, ErbB-2 - metabolism
- Trastuzumab - therapeutic use
- Find related publications in this database (Keywords)
- ADC
- HM2-MMAE
- (vic-)trastuzumab duocarmazine
- Trastuzumab deruxtecan
- TAK-522
- Trastuzumab emtansine
- anti-HER2
- PBD-MA
- HER2 low
- mode of action